Trump sent to Walter Reed Hospital. After the Regeneron

New Post Public Reply Private Reply Replies (0) Message Board
MarcS
855
Trump sent to Walter Reed Hospital. After the Regeneron cocktail does not work, they will look for other things to try. At that point the politics of drug approvals may not be as extreme because the President's life will be on the line. Someone may mention Leronlimab, watches a video of Samantha Monnet stating that leronlimab saved her life. Someone plays a video of a TEDx Speech by a former Medical Director of Diagnostic Virology at Stanford University Hospitals. Someone else says what are you waiting for, get the President leronlimab. Is this fantasy? Slightly, but not really, at this point there is a possibility of it happening. It's also a nightmare scenario, for the shorts.
1

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investors Monitor Class Action Against Xerox Ahead of Deadline

Updated Category News Views 313

Xerox Holdings Corporation Under Legal Scrutiny Faruqi & Faruqi, LLP, a prominent national securities law firm, is reaching out to investors of Xerox Holdings Corporation (NASDAQ: XRX) to inform them about an ongoing class action lawsuit. Investors are reminded of an important deadline for those wanting to assume the role of lead plaintiff in this case. The deadline for...

Continue Reading
UBS's Caution on Dr. Reddy's Projections Signals Concerns

Updated Category News Views 155

UBS dropped a Sell rating on Dr. Reddy's Laboratories (NSE: DRRD) back in 2024, tagging the stock with a price target of INR 5,700.00. You could feel the tension shift in trading rooms as their assessment sparked fresh chatter about the firm’s US base business revenue projections that seem downright optimistic. UBS Questions Revenue Estimates: Too High or Just Right?...

Continue Reading
Evaluating Apple's Business Landscape Among Top Tech Firms

Updated Category News Views 115

Assessing Market Position and Performance In the dynamic world of technology hardware, it’s crucial for investors to analyze the competition thoroughly. This article takes a closer look at Apple (NASDAQ: AAPL) and compares its financial metrics and market position against its key competitors in the industry. With this analysis, we aim to provide insights into Apple's...

Continue Reading
Back to School: Parents Prepare for Illness and Solutions

Updated Category News Views 191

Back to School: Parents Brace for Sickness A recent survey shows that as children head back to the classroom, many parents anticipate facing a wave of illnesses at home. Conducted by Boiron, a leader in homeopathic remedies, this nationwide survey reveals parents' concerns about the inevitable germs that come along with the school year. Survey Insights on Parental...

Continue Reading
Scarf Systems Achieves SOC 2 Type 2 Examination Success

Updated Category News Views 72

Scarf Systems, Inc. completed a SOC 2 Type 2 examination back in early 2023, solidifying its place as a frontrunner in data security. This wasn't just some routine check; it was a deep dive into how well Scarf protected customer data and adhered to stringent safety protocols. But here’s the kicker—traders started asking: is this enough to keep investors calm? What’s...

Continue Reading